Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04594642
Other study ID # D7400C00006
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 2, 2021
Est. completion date January 15, 2027

Study information

Verified date May 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or more prior lines of therapy.


Description:

The study consists of 3 parts. Part 1 Arm A is a dose escalation study allowing the assessment of safety, tolerability, PK and PD profiles of single-agent AZD0486. Part 2 Arm B will evaluate the MTD (or RP2D) of AZD0486 monotherapy in subjects with biopsy proven RR DLBCL and HGBL. This will be initiated once expansion dose has been selected based on data from Part 1 Arm A. Part 2 Arm C evaluate the MTD (or RP2D) of AZD0486 monotherapy in subjects with biopsy proven RR FL. Arm C will be initiated once the expansion dose for FL has been selected based on data from the Monotherapy Dose Escalation (Part 1, Arm A). The expansion dose and dosing frequency for Part 2 will be chosen by the SMG based on safety, tolerability, and PK/PD data collected during the dose escalation portion of the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 206
Est. completion date January 15, 2027
Est. primary completion date January 15, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 130 Years
Eligibility Inclusion Criteria: - Biopsy proven B-NHL, including DLBCL, HGBL, or FL. - For Arm B Only: Subject has biopsy proven DLBCL or HGBL - For Arm C only: Subject has biopsy proven FL - Subject has received at least 2 lines of therapy to which the subject has been either refractory or has subsequently relapsed. In order to be eligible for this study subjects must not be candidates for treatment regimens known to provide clinical benefit in B-NHL. - Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2. - Subject must have adequate liver, bone marrow and kidney function (eGFR = 50 mL/min). - Subject must have locally confirmed CD19 positivity (must be documented after time of progression from last CD19-targeted therapy, if received) - Subject must have at least 1 measurable disease site - Subject must have ANC >/= 1000/mm3, platelets >/= 50,000 mm3, hemoglobin >/= 8.0 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening - Subject must have a total bilirubin <1.5x ULN, AST/ALT < 3xULN Exclusion Criteria: - Subject has been diagnosed with or treated for another malignancy whose natural history or treatment may interfere with the safety or efficacy assessment of the investigational regimen. - Subject has a history of central nervous system (CNS) involvement by their B-NHL - Subject has a history of leukemic presentation of their B-NHL. - Subject has history or presence of clinically significant CNS pathology - Subject has CNS involvement from active or history of autoimmune disease. - Subject experienced Grade = 3 cytokine release syndrome (CRS) following prior T-cell engager (TCE) or CAR T-cell therapy. - Subject experienced Grade = 2 neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) following prior TCE or CAR T-cell therapy. - Subject has received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study drug treatment or has received an SCT and requires ongoing immunosuppressive therapy. - Subjects with human immunodeficiency virus (HIV) infection, or subjects with chronic or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Subjects with chronic HBV may be enrolled if the HBV viral load is undetectable on suppressive therapy, or if the subject has a documented cure. Subjects with HCV who have a documented cure may be enrolled. - Subject has a history of major cardiac abnormalities. - If female, subject must not be pregnant or breastfeeding.

Study Design


Intervention

Drug:
AZD0486 IV
AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells

Locations

Country Name City State
Australia Research Site Bedford Park
Australia Research Site Heidelberg
Australia Research Site Hobart
Australia Research Site Melbourne
Japan Research Site Chuo-ku
Japan Research Site Koto-ku
Japan Research Site Nagoya-shi
Japan Research Site Yamagata-shi
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Taiwan Research Site Kaohsiung City
Taiwan Research Site Kweishan
Taiwan Research Site Tainan
Taiwan Research Site Taipei
United States Research Site Austin Texas
United States Research Site Charlotte North Carolina
United States Research Site Columbus Ohio
United States Research Site Houston Texas
United States Research Site Louisville Kentucky
United States Research Site Milwaukee Wisconsin
United States Research Site New Brunswick New Jersey
United States Research Site Pittsburgh Pennsylvania
United States Research Site Portland Oregon
United States Research Site Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Australia,  Japan,  Korea, Republic of,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of subjects with Dose-limiting toxicities (DLT) A DLT is defined as a TEAE that is not unequivocally due to the subject's underlying malignancy or other extraneous cause. DLT evaluable subjects are defined as those subjects who receive either the target dose of AZD0486 or priming dose(s) in any step-up dose schedule and are assessed for toxicities for the 28-day evaluation period.
The NCI-CTCAE version 5.0 will be used (except for CRS and NT). A DLT will be evaluated as Non-hematologic, Hematologic, Cytokine Release Syndrome (CRS), or neurotoxicity.
28 days
Primary Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs) The incidence, timing, seriousness, and relationship to study treatment of adverse events will be evaluated. From screening until 90 Days after end of treatment
Primary Maximum Observed Serum Concentration of AZD0486 (Cmax) The maximum observed serum concentration on a concentration time curve. 4 weeks
Primary Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) Area under the serum concentration-time curve from time zero to time of last measurable concentration. 4 weeks
Primary Apparent terminal half-life (t1/2) of AZD0486 Terminal half-life (t1/2,) will be determined after infusion in Cycle 1 using non-compartmental methods. From screening until 90 Days after end of treatment
Secondary Anti-Lymphoma Activity by Objective Response Rate (ORR) Objective response rate is defined as the proportion of subjects with a confirmed partial or complete response to treatment 48 months
Secondary Anti-Lymphoma Activity by Progression-Free Survival (PFS) Progression-free survival time is defined as the time from the first dose of AZD0486 to progression or death, whichever occurs first 48 months
Secondary Anti-Lymphoma Activity by Duration of Objective Response (DOR) The duration of objective response for a subject is defined as the time from the initial objective response to disease progression or death, whichever occurs first 48 months
Secondary Anti-Lymphoma Activity by Clinical Benefit Rate Clinical benefit rate is defined as the proportion of subjects with a confirmed complete response, partial response or minor response, or stable disease for at least 24 weeks after responding to treatment 48 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03078855 - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Phase 3
Active, not recruiting NCT03245021 - Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A Phase 1
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02213263 - A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Phase 3
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Terminated NCT00772668 - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL N/A
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Terminated NCT02204982 - Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma Phase 3
Completed NCT02536664 - Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Terminated NCT00850499 - Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab Phase 2
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Terminated NCT00136591 - A Phase 2 Study of Velcadeā„¢ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma Phase 2
Not yet recruiting NCT06068881 - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Phase 2
Completed NCT04034056 - Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)